Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - cancer%2foncology
108
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
MEK7 inhibitors for acute lymphoblastic leukemia (ALL) treatment
NU 2023-060 INVENTORS Karl Scheidt* Dalton Kim Meghan Orr SHORT DESCRIPTION Rational design of highly potent and selective covalent MEK7 inhibitors BACKGROUND Acute lymphoblastic leukemia (ALL) is a deadly blood cancer, the most common hematological malignancy in patients under 14 years of age. Despite advancements in treatment, ALL relapse...
Published: 8/10/2026
|
Updated: 8/10/2026
|
Inventor(s):
Keywords(s):
ALL - Acute Lymphoblastic Leukemia
,
Cancer/Oncology
,
Leukemia
,
Small molecule
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Covalent MEK4 Inhibitors for Targeted Cancer Therapy
NU 2025-154 INVENTORS Karl Scheidt* Gina Connors SHORT DESCRIPTION This technology introduces novel covalent inhibitors of MEK4, built upon previously-developed reversible inhibitors (see NU2019-059 and NU2021-217). A covalent inhibition strategy offers enhanced potency, selectivity, and prolonged duration of action compared to reversible...
Published: 8/10/2026
|
Updated: 8/10/2026
|
Inventor(s):
Keywords(s):
Cancer/Oncology
,
Covalent Inhibition
,
Kinase Inhibitor
,
Leukemia
,
MEK4
,
MEK7
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Improved MEK4 Inhibitors for the Treatment of Cancer
NU 2021-217 INVENTORS Karl Scheidt* Ada Jade Kwong Hidayatullah Munshi Thao Nguyen Pham SHORT DESCRIPTION This technology introduces novel indazole derivatives as potent and selective MEK4 inhibitors for cancer treatment, particularly in advanced prostate cancer and pancreatic adenocarcinoma. The lead molecule is optimized over first-generation...
Published: 8/10/2026
|
Updated: 8/10/2026
|
Inventor(s):
Keywords(s):
Cancer/Oncology
,
Pancreatic cancer
,
Prostate cancer
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
CD40L-targeted therapies for myeloid diseases
NU 2016-012 INVENTORS Peng Ji* Kehan Ren Ermin Li SHORT DESCRIPTION Methods of targeting CD40L for treating TET2-mutant pre-malignant myeloid conditions BACKGROUND TET2 is one of the most frequently mutated genes in myeloid neoplasms and their precursor conditions, such as clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia...
Published: 8/3/2026
|
Updated: 8/3/2026
|
Inventor(s):
Keywords(s):
AML - Acute myeloid leukemia
,
Cancer Treatment
,
Cancer/Oncology
,
Immunotherapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
CD73-PROTACs for Cancer Therapy
SHORT DESCRIPTION A novel first-in-class proteolysis targeting chimera (PROTAC) that selectively degrades CD73 to reverse tumor immune evasion and inhibit cancer progression. INVENTORS Bin Zhang* Northwestern University Feinberg School of Medicine, Department of Medicine (Hematology & Oncology) Gary Schiltz* Weinberg...
Published: 7/6/2026
|
Updated: 7/6/2026
|
Inventor(s):
Keywords(s):
BIO2026
,
Breast cancer
,
Cancer/Oncology
,
Colon cancer
,
Lung cancer
,
Melanoma
,
PROTAC
,
Targeted therapy
,
Therapeutics
,
TPD - Targeted protein degradation
Category(s):
Life Sciences > Therapeutics
Polycomb Repressive Complex 1 (PRC1) Inhibitors to Restore Immune Response in B-Cell Lymphomas
SHORT DESCRIPTION A therapeutic approach that restores MHC-II expression using PRC1 inhibitors to reactivate anti-tumor immunity in B-cell lymphomas. INVENTORS Lu Wang* Zibo Zhao * Principal Investigator NU Tech ID: NU 2025-010 IP STATUS U.S. Provisional Patent Application has been filed. THERAPEUTICS...
Published: 6/25/2026
|
Updated: 6/23/2026
|
Inventor(s):
Keywords(s):
Cancer/Oncology
,
Immunotherapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Protein Degraders of NSD2 for Targeted Treatment of Head and Neck Cancers
SHORT DESCRIPTION Targeted protein degraders that selectively eliminate NSD2 for improved treatment of head and neck cancers. INVENTORS Gary Schiltz* Weinberg College of Arts and Sciences, Department of Chemistry Yanis Boumber * Principal Investigator NU Tech ID: NU 2023-140 IP STATUS U.S....
Published: 6/16/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s):
BIO2026
,
Cancer/Oncology
,
Head and neck cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2016-137B INVENTORS Richard Silverman Weinberg College of Arts and Sciences, Department of Chemistry SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer) as well as neurodegenerative...
Published: 6/17/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s):
AD - Alzheimer’s Disease
,
ALS - Amyotrophic Lateral Sclerosis
,
AUTM26C1
,
BIAUTM1
,
BIO2026
,
Cancer/Oncology
,
HD - Huntington's Disease
,
Melanoma
,
Neurodegenerative disease
,
Neuroinflammation
,
Neurologic disease
,
nNOS
,
PD - Parkinson's Disease
,
Small molecule
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Peptide Linkers for Modulating Antigen Immune Response in Cancer Vaccines
SHORT DESCRIPTION A novel non-biologically derived peptide linker technology enabling precise intracellular release of vaccine antigens to enhance immune activation. NU TECH ID NU 2024-124 INVENTORS Chad Mirkin* Weinberg College of Arts and Sciences, Department of Chemistry Tanner Fink ...
Published: 7/21/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s):
BIO2026
,
Cancer/Oncology
,
Immunology
,
Immunotherapy
,
Infectious disease
,
Therapeutics
,
Vaccine
Category(s):
Life Sciences > Therapeutics
Biomimetic HDL Nanoparticles for Treatment of Cancer, Immune and Inflammatory Disorders, and Cardiovascular Disease
SHORT DESCRIPTION Self-assembling biomimetic high-density lipoprotein nanoparticle (HDL NP) platform technology with a soft organic core, designed to more closely replicate key functional properties of mature human HDL for therapeutic use in cardiovascular disease, cancer, and inflammatory/immune disorders. INVENTORS Colby Thaxton* Northwestern...
Published: 7/29/2026
|
Updated: 6/16/2026
|
Inventor(s):
Keywords(s):
Atherosclerosis
,
Autoimmune disease
,
BIO2026
,
Breast cancer
,
Cancer/Oncology
,
Cardiology and Cardiovascular disease
,
Gene therapy
,
Immunology
,
Immunotherapy
,
Inflammation
,
Nanomaterials
,
Nanoparticle
,
Nanotechnology
,
Nucleic Acids
,
Platform technology
,
Prostate cancer
,
Research tool
,
Small molecule
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Biomarkers & Biomedical Research Tools
,
Life Sciences > Healthcare Devices, Tools & IT
,
Life Sciences > Therapeutics
1
2
3
4
5
6
7
8
9
10
...